AG
PTGX icon

Algert Global’s Protagonist Therapeutics PTGX Stock Holding History

Algert Global’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
87,698
+9,228
+12% +$964K 0.13% 244
2026
Q1 		$8.27M Buy
78,470
+73,380
+1,442% +$6.5M 0.12% 269
2025
Q4 		$445K Buy
+5,090
New +$417K 0.01% 962
2025
Q3 		– Sell
-13,055
Closed -$722K – 1302
2025
Q2 		$722K Sell
13,055
-5,610
-30% -$269K 0.02% 867
2025
Q1 		$903K Buy
18,665
+945
+5% +$39.6K 0.02% 788
2024
Q4 		$684K Sell
17,720
-97,959
-85% -$4.27M 0.02% 863
2024
Q3 		$5.21M Sell
115,679
-36,400
-24% -$1.47M 0.14% 238
2024
Q2 		$5.27M Buy
152,079
+4,236
+3% +$124K 0.18% 165
2024
Q1 		$4.28M Buy
147,843
+72,083
+95% +$1.96M 0.17% 201
2023
Q4 		$1.74M Buy
75,760
+2,930
+4% +$51.3K 0.07% 459
2023
Q3 		$1.21M Buy
72,830
+45,600
+167% +$885K 0.06% 523
2023
Q2 		$752K Buy
27,230
+6,170
+29% +$154K 0.03% 719
2023
Q1 		$484K Sell
21,060
-63,112
-75% -$1.06M 0.02% 828
2022
Q4 		$918K Buy
84,172
+13,240
+19% +$112K 0.05% 605
2022
Q3 		$598K Sell
70,932
-17,165
-19% -$162K 0.04% 747
2022
Q2 		$697K Buy
88,097
+63,780
+262% +$771K 0.05% 624
2022
Q1 		$576K Buy
+24,317
New +$685K 0.04% 757
2019
Q3 		– Sell
-15,517
Closed -$188K – 423
2019
Q2 		$188K Buy
15,517
+5,030
+48% +$55.6K 0.07% 280
2019
Q1 		$132K Sell
10,487
-3,554
-25% -$31.4K 0.08% 269
2018
Q4 		$94K Sell
14,041
-30,436
-68% -$241K 0.03% 357
2018
Q3 		$458K Sell
44,477
-7,430
-14% -$64K 0.1% 259
2018
Q2 		$349K Buy
+51,907
New +$398K 0.07% 273

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Algert Global's PTGX Position: Q2 2026 in Review

Algert Global increased its Protagonist Therapeutics (PTGX) stake by 12% in Q2 2026, buying an estimated $964K and bringing the position to 87,698 shares worth $10.8M. The position accounts for 0.13% of the portfolio, ranked #244.

Algert Global first reported a position in PTGX in Q2 2018 and has held it in 22 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Algert Global held 87,698 shares of Protagonist Therapeutics worth $10.8M as of Q2 2026.
  • Algert Global bought 9,228 Protagonist Therapeutics shares in Q2 2026, an estimated $964K.
  • Protagonist Therapeutics made up 0.13% of Algert Global's portfolio in Q2 2026, its #244 holding.
  • Algert Global first reported a position in Protagonist Therapeutics in Q2 2018 and has held it in 22 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.